Temozolomide

Temozolomide is an anti-cancer oral drug. It is used in chemotherapy. It is categorized as an alkylating agent. Temozolomide is used in the treatment of anaplastic and glioblastoma multiforme.

This medicine is used for the treatment of adult patients with refractory (first relapse) anaplastic astrocytoma who have experienced disease progression on nitrosourea and procarbazine.

On using Temozolomide you may experience side effects such as nausea, constipation, headache, weakness, paleness, reduced appetite, hair loss, low cognitive and memory skills and vomiting. Seek the help of your health care provider if your reactions persist and keep worsening over time.

As a precautionary measure, inform your doctor if: you are taking any prescription or non-prescription medications, you are allergic to this drug or any other medicines, or foods or substances, you are planning to take any vaccines, you are pregnant or are planning to become pregnant, or are nursing a baby.

The dosage for Temozolomide will be determined by your doctor taking into consideration your requirements. It comes in a capsule form of 5 mg, 20 mg, 100 mg and 250 mg. Usually, the daily dosage for adults ranges somewhere between 150-200 mg.

Take the medicine on an empty stomach either two hours or one hour prior to your meals or at bedtime. Dose-limiting toxicity is hematological. In the event of an overdose, hematological evaluation is necessary. Treatment is supportive.

Swallow capsules whole with a glass of water. Take on an empty stomach at similar time each day. If you have nausea and vomiting, contact healthcare provider for medicine to decrease this.

Male and female patients who take Temozolomide should protect against pregnancy (use effective contraception). Do not breast-feed while on medicine. Blood work necessary on day 22 and day 29 of each cycle to determine when to start next cycle and how much medicine to give.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Brain Tumor

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Hypersensitivity

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Nausea

• Headache

• Vomiting

• Weakness

• Loss Of Appetite

• Fatigue

• Hair Loss

• Viral Infections

• Convulsions

• Insomnia (Difficulty In Sleeping)

• Fever

• Decreased White Blood Cell Count

• Reduced Blood Platelets

• Coordination Disorder

• Diarrhoea

• Dizziness

• Constipation

• Rash

• Hemiparesis (Weakness On One Side Of The Body)

• Memory Loss

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Is It safe with alcohol?

  Interaction with alcohol is unknown. Please consult your doctor.

• Are there any pregnancy warnings?

  Temozolomide is unsafe to use during pregnancy.
  There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk, for example in life-threatening situations. Please consult your doctor.

• Are there any breast-feeding warnings?

  Temozolomide is probably unsafe to use during breastfeeding. Please consult your doctor.

• Is it safe to drive while on this medicine?

  Caution is advised when driving or operating machinery.

• Does this affect kidney function?

  Caution should be used when administered to patients with severe renal impairment (Clcr <39 mL/minute).

• Does this affect liver function?

  Caution should be used when administering to patients with severe hepatic impairment. Please consult doctor before consuming the drug.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Are there any missed dose instructions?

  The active constituent of this medication is activated once it has been converted into physiologic pH to MTIC. MTIC afterwards alkylates DNA at the N7 position of guanine, 06 positions of guanosine and 03 positions of adenosine.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

Below is the list of medicines, which contains Temozolomide as ingredient

• Nublast 20Mg Capsule

  Zydus Cadila

• Temolon 250Mg Capsule

  Celon Laboratories Ltd

• Temotrust 100Mg Capsule

  Panacea Biotec Ltd

• Glistroma 250Mg Capsule

  Alkem Laboratories Ltd

• Tolmd 2.5Mg Tablet

  Torrent Pharmaceuticals Ltd

• Temcad 20Mg Tablet

  Cadila Pharmaceuticals Ltd

• Gliotem 250Mg Capsule

  Sun Pharmaceutical Industries Ltd

• Temodal 100Mg Capsule

  Fulford India Ltd

• Temolon 20Mg Capsule

  Celon Laboratories Ltd

• Tabze 250Mg Capsule

  Neon Laboratories Ltd

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

Temozolomide is activated once it has been converted into physiologic pH to MTIC. MTIC afterwards alkylates DNA at N7 position of guanine, 06 position of guanosine and 03 position of adenosine.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

Whenever you take more than one medicine, or mix it with certain foods or beverages, you"re at risk of a drug interaction.

test

• Interaction with Medicine

  Although valproic acid reduces the clearance of Temozolomide by 5%, the clinical significance of this is unknown.

• Interaction with Food

  Food reduces rate and extent of absorption. In addition, the incidence of nausea/vomiting is decreased when the drug is taken on an empty stomach.

• Interaction with Disease

  Prior to dosing, patients must have an absolute neutrophil count (ANC) of greater than or equal to 1.5 x 10 9/L and a platelet count of greater than or equal to 100 x 10 9/L. Must have ANC >1,500/mL, platelet count >100,000/mL before starting each cycle. Geriatric patients and women have a higher incidence of myelosuppression. Safety/efficacy in pediatrics not established. Use caution in patients with severe hepatic or renal impairment. The U.S. Food and Drug Administration (FDA) currently recommends that procedures for proper handling and disposal of antineoplastic agents be considered.

• Temozolomide- Drug Information Portal [Internet]. druginfo.nlm.nih.gov. 2019 [Cited 3 December 2021]. Available from:

  https://druginfo.nlm.nih.gov/drugportal/name/temozolomide

• TEMOZOLOMIDE capsule- Daily Med [Internet]. dailymed.nlm.nih.gov. 2020. [Cited 3 December 2021]. Available from:

  https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d599ccf-8e63-4ff1-aa52-4809744ea97a

• Temodal Capsules- EMC [Internet]. www.medicines.org.uk. 2021 [Cited 23 Nov 2021]. Available from:

  https://www.medicines.org.uk/emc/product/1463/smpc